4.8 Article

Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells

Journal

FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.853894

Keywords

mesenchymal stem cells; experimental colitis; regulatory B cells; THBS1; TGF beta (transforming growth factor beta)

Categories

Funding

  1. National Key Research and Development Program of China, Stem Cell and Translational Research [2017YFA0105501, 2018YFA0107203]
  2. National Natural Science Foundation of China [81730005, 81971526, 81970109]
  3. Key Scientific and Technological Projects of Guangdong Province [2019B020236004, 2019B020234001, 2019B020235002, 2017B020230004, 2015B020226002]
  4. Guangdong Basic and Applied Basic Research Foundation [2020A1515010272]
  5. Key Scientific and Technological Program of Guangzhou City [201803040011]

Ask authors/readers for more resources

Intraperitoneally delivered mesenchymal stem cells (MSCs) secrete THBS1 to boost IL-10(+)Bregs and control the progression and recurrence of inflammatory bowel disease (IBD).
Mesenchymal stem cells (MSCs) show promising therapeutic potential in treating inflammatory bowel disease (IBD), and intraperitoneal delivery of MSCs have become a more effective route for IBD treatment. However, the underlying mechanisms are still poorly understood. Here, we found that intraperitoneally delivered MSCs significantly alleviated experimental colitis. Depletion of peritoneal B cells, but not macrophages, clearly impaired the therapeutic effects of MSCs. Intraperitoneally delivered MSCs improved IBD likely by boosting the IL-10-producing B cells in the peritoneal cavity, and a single intraperitoneal injection of MSCs could significantly prevent disease severity in a recurrent mouse colitis model, with lower proinflammation cytokines and high level of IL-10. The gene expression profile revealed that thrombospondin-1 (THBS1) was dramatically upregulated in MSCs after coculture with peritoneal lavage fluid from colitis mice. Knockout of THBS1 expression in MSCs abolished their therapeutic effects in colitis and the induction of IL-10-producing B cells. Mechanistically, THBS1 modulates the activation of transforming growth factor-beta (TGF-beta), which combines with TGF-beta receptors on B cells and contributes to IL-10 production. Blocking the interaction between THBS1 and latent TGF-beta or inhibiting TGF-beta receptors (TGF-beta R) significantly reversed the THBS1-mediated induction of IL-10-producing B cells and the therapeutic effects on colitis. Collectively, our study revealed that intraperitoneally delivered MSCs secreted THBS1 to boost IL-10(+)Bregs and control the progression and recurrence of colitis, providing new insight for the prevention and treatment of IBD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available